MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
India's Third Giant Leap
This Could be One of the Biggest Opportunities for Investors
- Home
- Todays Market
- Indian Stock Market News January 12, 2021
Sensex Trades Marginally Higher; Dow Futures Up by 39 Points Tue, 12 Jan 12:30 pm
Share markets in India are presently trading marginally higher.
The BSE Sensex is trading up 18 points, up 0.04% at 49,287 levels.
Meanwhile, the NSE Nifty is trading up by 15 points.
Tata Motors and Eicher Motors are among the top gainers today. Divi's Laboratories and Asian Paints are among the top losers today.
The BSE Mid Cap index is trading up by 0.8%.
The BSE Small Cap index is trading up by 0.4%.
On the sectoral front, stocks from the real estate sector are witnessing most of the buying interest.
On the other hand, stocks from the FMCG sector, are witnessing most of the selling pressure.
US stock futures are trading higher today, indicating a positive opening for Wall Street indices.
Nasdaq Futures are trading up by 32 points (up 0.2%) while Dow Futures are trading up by 39 points (up 0.1%).
The rupee is trading at 73.35 against the US$.
Gold prices are trading up 0.3% at Rs 49,465 per 10 grams.
In international markets, gold prices edged higher but a stronger US dollar capped gains.
Amid mixed global cues, gold and silver prices in India continued their volatile ride of the year. On MCX, February gold futures edged 0.03% lower to Rs 49,328 per 10 grams while silver futures declined 0.2% to Rs 65,414 per kg. In the previous session, gold prices had risen 0.7% after a massive fall on Friday last week.
To know more about gold, check out our article on how to invest in gold here: How to Invest in Gold?
Speaking of gold and silver?utm_source=TM&utm_medium=website&utm_campaign=MCOM&utm_content=market-commentary" https://www.equitymaster.com/timeless-reading/39/how-to-invest-in-silver?utm_source=TM&utm_medium=website&utm_campaign=MCOM&utm_content=market-commentary" target="_blank">silver?utm_source=TM&utm_medium=website&utm_campaign=MCOM&utm_content=market-commentary" target="_blank">silver, India's #1 trader, Vijay Bhambwani talks about why he is more bullish on silver?utm_source=TM&utm_medium=website&utm_campaign=MCOM&utm_content=market-commentary" https://www.equitymaster.com/timeless-reading/39/how-to-invest-in-silver?utm_source=TM&utm_medium=website&utm_campaign=MCOM&utm_content=market-commentary" target="_blank">silver?utm_source=TM&utm_medium=website&utm_campaign=MCOM&utm_content=market-commentary" target="_blank">silver than gold, and why it's a great investment for 2021 and beyond, in one of his videos for Fast Profits Daily.
Tune in here to find out more:
Moving on to stock specific news...
Among the buzzing stocks today is Tata Motors.
Tata Motors-owned Jaguar Land Rover (JLR) on January 11 released its 2020 sales figures, which reflected a considerable hit as a result of the Covid-19 pandemic but highlighted signs of recovery as sales in China remained strong.
For the calendar year 2020, retail sales for Jaguar Land Rover were 425,974 (vehicles), down 23.6% from 2019, reflecting the industry impact of Covid-19 particularly in the first half of the year when plants were shut down for more than two months.
However, the company said it has since seen sales increase quarter-on-quarter (QoQ) by over 53% in the quarter ended September 30, 2020, followed by a 13.1% increase in the most recent quarter.
Retail sales for the quarter ending December 31, 2020 were 128,469 vehicles, 13.1% higher than the 113,569 vehicles sold in the preceding quarter, but down 9% on the same period last year. The company said China sales were particularly encouraging as they were up 20.2% on the prior quarter and 19.1% year-on-year (YoY).
We will keep you posted on more updates from this space. Stay tuned.
At the time of writing, Tata Motors share price was trading up 10.2% on the BSE.
Moving on to news from the indian pharma sector...
Dr Reddy's Gets Nod To Conduct Phase-3 Trial Of Covid-19 Vaccine
Dr Reddy's on January 11 announced that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from Phase 2 of the clinical trial of the Sputnik V vaccine and has recommended Phase 3 recruitment of the clinical trial without any modifications.
"The safety data from the phase 2 clinical trial from India is very positive, and confirms the safety profile of Sputnik V in the international markets. The Sputnik V consistently shows safety and high efficacy in international clinical trials as it is based on a safe human adenoviral vector platform," Dr Reddy's said in a statement.
The phase 2 study of Sputnik V was conducted on 100 subjects as part of a randomized, double-blind, parallel-group, placebo-controlled study in India. The DSMB concluded that no safety concerns were identified and the study has met the primary endpoints of safety, Dr Reddy's said.
The clinical trials are being conducted by JSS Medical Research as the clinical research partner in India. Dr. Reddy's has partnered with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT) for advisory support, THSTI (Translational Health Science and Technology Institute) for further immunogenicity data characterisation, and to use BIRAC's clinical trial centres for the vaccine.
Currently, the vaccine's clinical trials are underway in UAE, Egypt, Venezuela, and Belarus while it has been registered in Algeria, Argentina, Belarus, Bolivia, and Serbia for inoculation.
In September 2020, Dr. Reddy's and Russian Direct Investment Fund (RDIF) entered into a partnership to conduct the clinical trials of the Sputnik V vaccine and the rights for distribution in India.
Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the world's first registered vaccine against Covid-19 based on the established human adenoviral vector platform.
It currently ranks among the top 10 candidate vaccine on the World Health Organization's (WHO) list. The vaccine's efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials in Russia.
How this pans out remains to be seen. Meanwhile, stay tuned for more updates from this space.
Here's an interesting data on Dr. Reddy's Lab, investing just Rs 100,000 in Dr. Reddy's Labs in 1992, it would have given a whopping Rs 48.9 million in 2014!
To know more, you can access Dr Reddy's latest quarterly results on our website.
And to know what's moving the Indian stock markets today, check out the most recent share market updates here.
For information on how to pick stocks that have the potential to deliver big returns, download our special report now!
Read the latest Market Commentary
Indian Share Market Update: Top Gainers and Losers
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
Equitymaster requests your view! Post a comment on "Sensex Trades Marginally Higher; Dow Futures Up by 39 Points". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!